These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 12608439

  • 21. [Do inhaled corticosteroids reduce mortality in chronic obstructive pulmonary disease?].
    Bridevaux PO, Leuenberger P.
    Rev Med Suisse; 2005 Nov 16; 1(41):2673-4, 2677-9. PubMed ID: 16355882
    [Abstract] [Full Text] [Related]

  • 22. An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease.
    Singh S, Loke YK.
    Int J Chron Obstruct Pulmon Dis; 2010 Aug 09; 5():189-95. PubMed ID: 20714372
    [Abstract] [Full Text] [Related]

  • 23. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis.
    Sutherland ER, Allmers H, Ayas NT, Venn AJ, Martin RJ.
    Thorax; 2003 Nov 09; 58(11):937-41. PubMed ID: 14586043
    [Abstract] [Full Text] [Related]

  • 24. Inhaled corticosteroids and the risk of fracture in chronic obstructive pulmonary disease.
    Pujades-Rodríguez M, Smith CJ, Hubbard RB.
    QJM; 2007 Aug 09; 100(8):509-17. PubMed ID: 17609226
    [Abstract] [Full Text] [Related]

  • 25. Inhaled corticosteroids in chronic obstructive pulmonary disease: is there a clinical benefit?
    Man SF, Sin DD.
    Drugs; 2005 Aug 09; 65(5):579-91. PubMed ID: 15748094
    [Abstract] [Full Text] [Related]

  • 26. Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis.
    Baker WL, Baker EL, Coleman CI.
    Pharmacotherapy; 2009 Aug 09; 29(8):891-905. PubMed ID: 19637942
    [Abstract] [Full Text] [Related]

  • 27. Effect of outpatient therapy with inhaled corticosteroids on decreasing in-hospital mortality from pneumonia in patients with COPD.
    Yamauchi Y, Yasunaga H, Hasegawa W, Sakamoto Y, Takeshima H, Jo T, Matsui H, Fushimi K, Nagase T.
    Int J Chron Obstruct Pulmon Dis; 2016 Aug 09; 11():1403-11. PubMed ID: 27382276
    [Abstract] [Full Text] [Related]

  • 28. The use of long acting β₂-agonists, alone or in combination with inhaled corticosteroids, in chronic obstructive pulmonary disease (COPD): a risk-benefit analysis.
    Cave AC, Hurst MM.
    Pharmacol Ther; 2011 May 09; 130(2):114-43. PubMed ID: 21276815
    [Abstract] [Full Text] [Related]

  • 29. The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD.
    Hanania NA.
    Pulm Pharmacol Ther; 2008 May 09; 21(3):540-50. PubMed ID: 18280761
    [Abstract] [Full Text] [Related]

  • 30. Inhaled corticosteroids and mortality in COPD.
    Macie C, Wooldrage K, Manfreda J, Anthonisen NR.
    Chest; 2006 Sep 09; 130(3):640-6. PubMed ID: 16963657
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The role of corticosteroids in chronic obstructive pulmonary disease.
    Calverley PM.
    Semin Respir Crit Care Med; 2005 Apr 09; 26(2):235-45. PubMed ID: 16088440
    [Abstract] [Full Text] [Related]

  • 33. Effects of inhaled corticosteroids in monotherapy or combined with long-acting {beta}2-agonists on mortality among patients with chronic obstructive pulmonary disease.
    Cyr MC, Beauchesne MF, Lemière C, Aaron SD, Blais L.
    Ann Pharmacother; 2010 Apr 09; 44(4):613-22. PubMed ID: 20233915
    [Abstract] [Full Text] [Related]

  • 34. [Clinical efficacy of inhaled corticosteroids in COPD].
    Kamoi H, Yoshikawa T, Hirata K.
    Nihon Rinsho; 2007 Apr 09; 65(4):696-701. PubMed ID: 17419390
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Benefits and risks of inhaled corticosteroids in chronic obstructive pulmonary disease.
    Bonay M, Bancal C, Crestani B.
    Drug Saf; 2002 Apr 09; 25(1):57-71. PubMed ID: 11820912
    [Abstract] [Full Text] [Related]

  • 37. Impact of long-term treatment with low-dose inhaled corticosteroids on the bone mineral density of chronic obstructive pulmonary disease patients: aggravating or beneficial?
    Mathioudakis AG, Amanetopoulou SG, Gialmanidis IP, Chatzimavridou-Grigoriadou V, Siasos G, Evangelopoulou E, Mathioudakis GA.
    Respirology; 2013 Jan 09; 18(1):147-53. PubMed ID: 22985270
    [Abstract] [Full Text] [Related]

  • 38. Assessing the healthcare resource use associated with inappropriate prescribing of inhaled corticosteroids for people with chronic obstructive pulmonary disease (COPD) in GOLD groups A or B: an observational study using the Clinical Practice Research Datalink (CPRD).
    Chalmers JD, Poole C, Webster S, Tebboth A, Dickinson S, Gayle A.
    Respir Res; 2018 Apr 11; 19(1):63. PubMed ID: 29642882
    [Abstract] [Full Text] [Related]

  • 39. Inhaled corticosteroids and mortality in COPD.
    Omron E.
    Chest; 2007 Mar 11; 131(3):939; author reply 940. PubMed ID: 17380589
    [No Abstract] [Full Text] [Related]

  • 40. Pharmacotherapy for mortality reduction in chronic obstructive pulmonary disease.
    Sin DD, Man SF.
    Proc Am Thorac Soc; 2006 Sep 11; 3(7):624-9. PubMed ID: 16963545
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.